Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to test the safety and efficacy of a treatment
regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed
by withdrawal of efalizumab and maintenance therapy with sirolimus, for the prevention of the
destruction and rejection of islet transplants in type 1 diabetic recipients.
Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U.S. market
in April of 2009. Previously transplanted subjects have been transitioned to alternative
immunosuppressives and no new subjects will be transplanted under this protocol.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute